Clinical Intelligence/Clinical Efficiency

Two Top 5 Global Pharma Companies Affirm Their Trust in Calyx RIM

Ability to meet evolving requirements, including IDMP, ensures regulatory compliance for leading companies

Calyx, the eClinical and Regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that two of the world’s Top 5 pharmaceutical companies have chosen to continue using the Calyx Regulatory Information Management (RIM) system for streamlining and optimizing their regulatory affairs processes. Based on their successful experiences and trust in Calyx RIM, the organizations have extended their contracts for up to five years.

Both organizations are relying on Calyx RIM to ensure compliance with increasingly complex global publishing requirements and for the management and tracking of detailed product information, registrations, and authorizations. In addition to complying with regulations enacted to ensure patient safety worldwide, these leading global pharmaceutical companies will leverage Calyx RIM to adhere to the Identification of Medicinal Products (IDMP) standard that will begin having an impact on European registrations in 2022.

“By choosing to extend their use of Calyx RIM, these leaders in the pharmaceutical industry have substantiated the true value Calyx RIM delivers,” said Jo English, Vice President, Regulatory Information Management, Calyx. “We’re honored to have earned their trust and to continue delivering the robust tools they need to comply with IDMP and other regulatory requirements, ultimately helping patients around the world maintain access to much needed medical treatments.”

This marks three long-term Calyx RIM contract renewals signed by Top 10 Global Pharmaceutical companies in the past month.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to

Related posts

Anocca Raises $47M to Advance TCR-T Cellular Immunotherapy

Business Wire

Wugen Raises $172 Million for Clinical Stage Memory NK Cell Platform

Business Wire

entrinsic bioscience Secures $49 Million in Financing

PR Newswire